One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<
NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if the pharma decid
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access to new medical treatments and innovations.
Today, pharma brand planning teams can benefit from technology platforms that aggregate data and automate analyses, helping unlock insights on the market landscape and clinical environment